tldrdailynews.com logo
Tag

Autoimmune Diseases

All articles tagged with #autoimmune diseases

In-body CAR-T therapy shows early promise against multiple sclerosis
health1 month ago

In-body CAR-T therapy shows early promise against multiple sclerosis

A small NEJM trial reports that a single intravenous injection of a lentiviral vector instructs the body to generate CAR-T cells in vivo, which then deplete B cells and autoantibodies and correlate with improved motor and cognitive function, reduced fatigue, and lower inflammation in people with multiple sclerosis and other autoimmune diseases over about six months. This supports the concept of in‑vivo CAR-T therapy as a cheaper, faster approach, but efficacy must be confirmed in more participants.

via Nature|
#autoimmune-diseases#car-t-therapy#gene-therapy
Autoimmune CAR-T Trials Halt After Fatal IEC-HS Events
healthcare1 month ago

Autoimmune CAR-T Trials Halt After Fatal IEC-HS Events

Novartis has temporarily paused its autologous CD19 CAR-T program for autoimmune diseases after three IEC-HS–related deaths, affecting multiple phase 1/2 studies across lupus, systemic sclerosis, ANCA-associated vasculitis, myopathies and other conditions, with patient monitoring continuing. Bristol Myers Squibb has also paused enrollment in its autologous CD19 zola-cel autoimmune trials due to transient inflammatory events, though oncology programs remain active. Analysts suggest rapid manufacturing platforms (T-Charge, NEXT-T) may drive increased T‑cell expansion and toxicities, prompting a cautious safety review before resumption.

via Fierce Biotech|
#autoimmune-diseases#bms#car-t-therapy
Boulevard Bio debuts with $65M to target B cells in IgA nephropathy
business1 month ago

Boulevard Bio debuts with $65M to target B cells in IgA nephropathy

Boulevard Bio surfaced from stealth with $65 million in funding from Deerfield Management to advance three autoimmune drug candidates. Led by Mahesh Karande and co-founded with Georg Schett, the company’s lead asset BLVD101 is a bispecific BAFF/APRIL antibody for IgA nephropathy (IgAN) with a 12-week dosing schedule and favorable interim Phase 1 safety data. The portfolio also includes BLVD201, a trispecific CD19/BCMA/CD3 T-cell engager licensed from METiS Techbio, and BLVD301 in IND-enabling stages, underpinned by 3DC’s B-cell–focused platform and Metis’ NanoForge technology. Boulevard emphasizes multi-target, patient-centric approaches to address B-cell–driven autoimmune diseases.

via Fierce Biotech|
#autoimmune-diseases#baffapril#biotech-startup
The Limits of Longevity: Autoimmune Gastritis Strikes a Meticulously Tracked Life
health3 months ago

The Limits of Longevity: Autoimmune Gastritis Strikes a Meticulously Tracked Life

Bryan Johnson, a prominent longevity advocate who tracks nearly every aspect of his biology, revealed he has autoimmune gastritis, a chronic condition that damages the stomach lining and can progress silently over years. Experts note autoimmune diseases are common, often with unknown causes, and while they can be managed, they aren’t curable. Johnson’s case illustrates both the promise and the limits of intensive data-driven health monitoring and single-subject experiments, showing that even exhaustive biomarker data may miss slow-developing illnesses.

via Northeastern Global News|
#autoimmune-diseases#autoimmune-gastritis#health
Moderna bets on off-the-shelf in vivo CAR-T for autoimmune disease
technology3 months ago

Moderna bets on off-the-shelf in vivo CAR-T for autoimmune disease

Moderna disclosed its first in vivo CAR-T program, mRNA-6007, which uses a lipid nanoparticle to deliver CAR-T mRNA to CD4/CD8 T and NK cells to target and deplete pathogenic B cells in autoimmune diseases. Marketed as an off-the-shelf approach, it aims to simplify manufacturing and expand access versus traditional ex vivo CAR-T. The therapy is in early IND-enabling stages and is slated to enter the clinic next year, with lupus and other B-cell–mediated conditions among the initial targets; if successful, it could enable larger-scale development, including future oncology applications.

via Fierce Biotech|
#autoimmune-diseases#in-vivo-car-t#lupus
CAR-T Reset Reboots Immune System to Heal Three Autoimmune Diseases
health6 months ago

CAR-T Reset Reboots Immune System to Heal Three Autoimmune Diseases

A 47-year-old German woman with refractory autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome was treated with CAR-T cell therapy to eradicate rogue B cells and reboot her immune system. After exhausting standard therapies, this radical approach led to dramatic improvement and is described by doctors as a landmark in immunotherapy.

via ZME Science|
#aiha#aps#autoimmune-diseases
CAR-T immune reset cures trio of autoimmune diseases in patient
health6 months ago

CAR-T immune reset cures trio of autoimmune diseases in patient

A 47-year-old woman with autoimmune haemolytic anaemia (AIHA), immune thrombocytopenia (ITP) and antiphospholipid syndrome (APS) achieved rapid, lasting remission after CD19-targeted CAR-T cell therapy, effectively resetting her immune system and enabling a near-normal life; she has remained in treatment-free remission for about 14 months, while researchers note the need for trials to determine durability and wider applicability.

via The Guardian|
#aiha#aps#autoimmune-diseases
Endometriosis Seen as a Whole-Body Immune Disorder with Ripple Effects
health6 months ago

Endometriosis Seen as a Whole-Body Immune Disorder with Ripple Effects

Endometriosis is described as a systemic immune disorder driven by chronic inflammation, with elevated cytokines such as IL-6 and IL-1beta in the blood and immune cells that fail to clear lesions, producing ripple effects like fatigue, brain fog, and widespread pain beyond pelvic symptoms. A 2025 study linked endometriosis to roughly twice the odds of an autoimmune diagnosis within two years of onset, suggesting shared inflammatory mechanisms rather than a purely reproductive disease; reframing it as a whole-body immune condition could guide development of immune-modulating treatments and empower patients in healthcare settings.

via Live Science|
#autoimmune-diseases#cytokines#endometriosis
business6 months ago

Gilead to Acquire Ouro Medicines to Advance OM336 Autoimmune T Cell Engager, Eyes Galapagos Collaboration

Gilead Sciences will acquire Ouro Medicines for $1.675 billion upfront plus up to $500 million in milestones to add OM336, a BCMAxCD3 T cell engager, to its inflammation portfolio. OM336 has shown single‑cycle efficacy in autoimmune diseases such as AIHA and ITP and holds Fast Track and Orphan Drug designations with registrational studies expected in 2027. Gilead is also pursuing a strategic collaboration with Galapagos on Ouro assets, with Galapagos covering half of upfront and milestone payments, sharing development costs, and receiving 20%–23% royalties on net sales while Gilead retains worldwide commercialization rights (except Greater China). The deal aims to advance immune-reset therapies by depleting pathogenic B cells/plasma cells to reduce inflammation, potentially enabling durable drug‑free remission; regulatory and integration risks remain.

via Gilead Sciences|
#autoimmune-diseases#bcmaxcd3#business
Gilead to Acquire Ouro Medicines to Fast-Track T Cell Engager for Autoimmune Diseases
business6 months ago

Gilead to Acquire Ouro Medicines to Fast-Track T Cell Engager for Autoimmune Diseases

Gilead Sciences agreed to buy Ouro Medicines for $1.675 billion upfront plus up to $500 million in milestones to add OM336, a BCMAxCD3 T cell engager, to its inflammation portfolio. OM336 has shown rapid B cell depletion with a favorable safety profile in Phase 1/2 data and has FDA Fast Track and Orphan Drug designations, with registrational studies expected in 2027. Gilead is also in advanced talks for a collaboration with Galapagos, under which Galapagos would fund half of upfront and milestone payments, absorb Ouro’s operating assets, and receive 20-23% royalties on net sales while Gilead retains worldwide commercialization rights. The combined effort aims to accelerate immune-reset therapies for autoimmune diseases and potentially deliver durable, drug-free remission through BCMA-targeted T cell engagers.

via Business Wire|
#autoimmune-diseases#bcmaxcd3#business
Over 100 autoimmune diseases mainly affect women: key facts
health11 months ago

Over 100 autoimmune diseases mainly affect women: key facts

Autoimmune diseases, which can affect nearly every part of the body and are more common in women, occur when the immune system mistakenly attacks healthy tissues. There are over 100 such diseases, with symptoms ranging from mild to life-threatening, and diagnosis can be complex. Recent research offers hope for more targeted treatments and early interventions, with ongoing clinical trials showing promising results. The global market for autoimmune treatments is substantial, reflecting the widespread impact of these chronic conditions.

via abcnews.go.com|
#autoimmune-diseases#diagnosis#health